Figure 1
Figure 1. Systemic analysis of structural changes in lymphatic vessels in LYVE-1-Cre/iDTR mice after DT administration. (A) Schematic diagram of a working model of the LYVE-1-Cre/iDTR double-transgenic mouse (LCiDT) and the iDTR (control) mouse. (B) Kaplan-Meier survival curves after DT administration into control and LCiDT mice. (C) CD31+ blood vessels and LYVE-1+ lymphatic vessels of the ear skin, trachea, diaphragm, intestine, and inguinal lymph node. 4,6 Diamidino-2-phenylindole (DAPI) staining for nuclei. Scale bars, 100 μm. (D) Quantification of LYVE-1+ areas in different organs. Each group, n = 4. *P < .05. (E) LYVE-1+/Prox1+ lymphatic vessels in the submedullary region of the inguinal lymph node. Scale bars, 50 μm.

Systemic analysis of structural changes in lymphatic vessels in LYVE-1-Cre/iDTR mice after DT administration. (A) Schematic diagram of a working model of the LYVE-1-Cre/iDTR double-transgenic mouse (LCiDT) and the iDTR (control) mouse. (B) Kaplan-Meier survival curves after DT administration into control and LCiDT mice. (C) CD31+ blood vessels and LYVE-1+ lymphatic vessels of the ear skin, trachea, diaphragm, intestine, and inguinal lymph node. 4,6 Diamidino-2-phenylindole (DAPI) staining for nuclei. Scale bars, 100 μm. (D) Quantification of LYVE-1+ areas in different organs. Each group, n = 4. *P < .05. (E) LYVE-1+/Prox1+ lymphatic vessels in the submedullary region of the inguinal lymph node. Scale bars, 50 μm.

Close Modal

or Create an Account

Close Modal
Close Modal